Circulating tumor cells in patients with cervical cancer undergoing chemoradiotherapy combined with brachytherapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927436" target="_blank" >RIV/00064173:_____/24:43927436 - isvavai.cz</a>

Alternative codes found

RIV/61383082:_____/24:00001382 RIV/00216208:11110/24:10482823 RIV/00216208:11120/24:43927436

Result on the web

<a href="https://doi.org/10.62347/QIXJ7103" target="_blank" >https://doi.org/10.62347/QIXJ7103</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.62347/QIXJ7103" target="_blank" >10.62347/QIXJ7103</a>

Result language

angličtina

Original language name

Circulating tumor cells in patients with cervical cancer undergoing chemoradiotherapy combined with brachytherapy

Original language description

Circulating tumor cells (CTCs) have significant potential to become an important tool for monitoring the effects of treatment in solid tumors. The present study reports the occurance of CTCs in cervical cancer (CC) patients during radical chemoradiotherapy (CRT), including brachytherapy (BRT), and during the follow-up period. Patients diagnosed with CC treated with radical CRT were included in the study (n=30). A total of 167 CTC-tests (MetaCell((R))) were provided at predefined testing time points during the study follow-up (e.g., before CRT, after CRT, every three months of follow-up). In parallel with CTC-testing, SCC-Ag were measured to compare their predictive values during treatment. CTCs were present in 96% (25/26) of patients at the time of diagnosis and in 61% (14/23) after treatment. Patients who relapsed during the 36-month follow-up (n=10) showed an elevation in pre-treatment CTC- numbers, similarly there was a significant increase in pre-treatment SCC-Ag. As next, an increased number of CTCs was observed approximately 12 weeks before relapse was diagnosed by standard imaging modalities (MRI, US, PET-CT) in 3 of 4 patients. In addition to standardized vital cytomorphology of enriched CTCs, quantitative PCR (qPCR) was used to inform the nature of CTCs before treatment. Analysis revealed increased SOX2 and POUSF expression in CTCs in the group of patients with recurrence (P &lt; 0.02). Disease aggressiveness may be related to increased expression of stem cell markers, as found in samples from relapsed patients. CTCs may be an aid to assess tumor burden and disease aggressiveness. An increase in CTCs precedes an increase in SCC-Ag and confirmation of relapse by imaging, as shown in our study.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

American Journal of Cancer Research

ISSN

2156-6976

e-ISSN

2156-6976

Volume of the periodical

14

Issue of the periodical within the volume

7

Country of publishing house

US - UNITED STATES

Number of pages

12

Pages from-to

3614-3625

UT code for WoS article

001281845100004

EID of the result in the Scopus database

—